Efavirenz/lamivudine/tenofovir

From Wikipedia, the free encyclopedia
Efavirenz/lamivudine/tenofovir
Combination of
EfavirenzNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleoside reverse transcriptase inhibitor
Clinical data
Trade namesTelura, Symfi, Symfi Lo
Other namesEFV/3TC/TDF
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa618028
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Identifiers
KEGG

Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Telura among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[1] It combines efavirenz, lamivudine, and tenofovir disoproxil.[1] As of 2019, it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir.[2] It is taken by mouth.[1]

Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness.[1] Severe side effects may include depression, psychosis, or osteonecrosis.[1] In those with a history of epilepsy, it may increase the frequency of seizures.[1] Greater care should also be taken in those with kidney problems.[1] It is unclear if use during pregnancy is safe.[1][3]

It is on the World Health Organization's List of Essential Medicines.[4] The combination received tentative approval in the United States in 2014,[5] and was granted approval in February 2018.[6][7] Its availability and importance is supported by Medecins Sans Frontieres.[1]

It was approved as a generic medication in the United States in 2020.[8][9]

References[]

  1. ^ Jump up to: a b c d e f g h i "Efavirenz + lamivudine + tenofovir disoproxil fumarate (Addition) -- Adults". World Health Organization (WHO).
  2. ^ World Health Organization (July 2019). Policy brief: update of recommendations on first- and second-line antiretroviral regimens. World Health Organization. hdl:10665/325892. WHO/CDS/HIV/19.15. License: CC BY-NC-SA 3.0 IGO.
  3. ^ "Telura" (PDF). Mylan.in. 2014. Retrieved 13 December 2017.[dead link]
  4. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  5. ^ "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". U.S. Food and Drug Administration (FDA). Retrieved 13 December 2017.[dead link]
  6. ^ "Drug Approval Package: Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 15 August 2020.
  7. ^ "Drug Approval Package: Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 24 November 2018. Retrieved 15 August 2020.
  8. ^ "Office of Generic Drugs 2020 Annual Report". U.S. Food and Drug Administration (FDA). Retrieved 12 February 2021.
  9. ^ "Drug Approval Package: Efavirenz, Lamivudine and Tenofovir disoproxil". U.S. Food and Drug Administration (FDA). 26 November 2018. Retrieved 15 August 2020.

External links[]

Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""